Prime Medicine, Inc. Common Stock

Day range

$3.38 – $3.70

Open

$3.70

Prev close

$3.73

Volume

4.56M

Market cap

$676.54M

Shares out

181.38M

P/E

—

P/S

166.10

P/B

16.99

P/FCF

—

ROE

-472.0%

ROA

-75.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Material agreementsJul 8, 2026

  On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regarding the parties' 2019 Collaboration and License Agreement (the "Agreement"). In the Final Award, the Tribunal declared that PM647, the Company's development candidate for the treatment of Alpha-1 Antitrypsin Deficiency ("AATD"), is within the Company's "Field" as defined by the Agreement, and that the Company therefore did not breach the Agreement.

• Shareholder meetingsJun 8, 2026

  At the Annual Meeting, the Company's stockholders voted on the following matters... Proposal 1 – Each of the following nominees was elected as a Class I Director... Michael Kelly [received] 107,059,058 For votes and David Schenkein, M.D. [received] 87,522,409 For votes. Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: 139,989,201 For, 101,259 Against, 294,264 Abstentions.

• Equity activityApr 16, 2026

  Pursuant to the Employment Agreement, the Board approved the grant of a stock option to purchase 800,000 shares of the Company's common stock pursuant to the Company's 2022 Stock Option and Incentive Plan (the "2022 Plan") to Ms. Makhni. The stock option award will have an exercise price equal to the closing price of the Company's common stock on the Nasdaq Global Market on the date of grant. Twenty-five percent of the shares will vest on the one-year anniversary of the date of the grant and the balance will vest monthly in equal installments over the following 36 months, subject to Ms. Makhni's continuous service. In addition, the Board approved the grant of a stock option to purchase 100,000 shares of the Company's common stock pursuant to the 2022 Plan to Ms. Makhni.

• Investor communicationsMar 3, 2026

  On March 3, 2026, the Company posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

• Investor communicationsJan 12, 2026

  On January 12, 2026, Prime Medicine, Inc. (the "Company") posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• BEAMBeam Therapeutics Inc. Common Stock-2.08%
• CRSPCRISPR Therapeutics AG-1.20%

Days to cover

8.4

Short interest

32.12M

Avg volume

3.8M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
  positiveZacks Investment Research· Oct 12, 2026
• Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
  positiveGlobeNewswire Inc.· Oct 5, 2026
• Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
  positiveThe Motley Fool· Jun 15, 2026
• The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
  positiveBenzinga· Mar 31, 2026
• Prime Medicine to Participate in Upcoming Investor Conferences
  neutralGlobeNewswire Inc.· Feb 25, 2026